Biomarker Assessment for Cell Therapy Toxicity and Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for adoptive cell therapy in treating B cell malignancies, such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), face challenges in predicting and mitigating toxicity, particularly neurotoxicity, and in optimizing treatment responses, as existing approaches often rely on post-symptom intervention and may not adequately prevent severe toxicities or enhance efficacy.
Innovation Solution
The methods involve assessing pre-treatment biomarkers like lymph node tumor burden, blood tumor burden, and cytokine levels (e.g., TNF, IL-16) to predict toxicity risk and treatment response, allowing for personalized dosing and administration strategies, including reduced dosing or alternative treatments for subjects at high risk of neurotoxicity, and selecting subjects likely to respond based on biomarker thresholds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell therapy is administered to treat B cell malignancies, then treatment response is improved, but toxicity risk increases
Solution Approach 1:
The patent applies preliminary action by assessing biomarkers (lymph node tumor burden, blood tumor burden, cytokine levels) before administering cell therapy to predict toxicity risk and treatment response. This pre-treatment assessment allows for personalized dosing decisions and patient selection, enabling the system to prepare appropriate intervention strategies in advance for patients at high risk of toxicity.
Solution Approach 2:
The patent implements feedback by continuously monitoring biomarker levels and treatment response during and after cell therapy administration. The system uses this feedback information to adjust future treatment decisions, identify patients who require additional supportive care, and refine dosing strategies based on observed outcomes and toxicity patterns.
2Productivity
If standard dosing is used for cell therapy, then treatment efficacy is maximized, but severe toxicity occurs more frequently
Solution Approach 1:
The patent applies parameter changes by adjusting cell therapy dosing based on individual patient biomarker profiles. Instead of using a fixed standard dose, the system modifies dosing parameters (dose amount, administration timing, supportive care intensity) according to measured lymph node tumor burden, blood tumor burden, and cytokine levels, thereby optimizing efficacy while minimizing severe toxicity for each patient.
Solution Approach 2:
The patent implements local quality by tailoring treatment parameters to individual patient characteristics rather than applying a uniform approach. Each patient receives a customized dosing strategy based on their specific biomarker profile, allowing the system to adapt the quality and intensity of treatment to local patient needs and risk profiles.
3Device complexity
If post-symptom intervention is used, then treatment simplicity is maintained, but toxicity prevention is insufficient
Solution Approach 1:
The patent transitions from post-symptom intervention to preliminary action by assessing toxicity risk biomarkers before treatment begins. This pre-treatment evaluation identifies patients at high risk of severe toxicity in advance, allowing for proactive prevention strategies, dosing adjustments, or alternative treatment options to be implemented before toxicity occurs.
Solution Approach 2:
The patent establishes a feedback loop that monitors biomarker changes during treatment and uses this information to guide real-time decision-making. The system continuously evaluates treatment response and toxicity markers, enabling dynamic adjustment of supportive care and dosing strategies to prevent severe toxicity while maintaining treatment efficacy.
Data Source
AI summary
Provided are methods for determining the risk of toxicity (e.g., neurotoxicity) and/or the likelihood of response to a cell therapy. In some aspects, the methods generally involve assessing parameters or biomarkers (e.g., blood analytes) that are associated with toxicity and/or response. In some aspects, the methods relate to adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, such as chronic lymphocytic leukemia (CLL), such as relapsed or refractory CLL, or small lymphocytic lymphoma (SLL). The cells for the adoptive cell therapy generally express recombinant receptors such as chimeric antigen receptors (CARs). In some aspects, the methods can be used to identify or select subjects for treatment, for example, with a cell therapy.